KC7F2|cas 927822-86-4|DC Chemicals

Cas No.:	927822-86-4
Chemical Name:	KC7f2
Synonyms:	KC7F2;2,5-dichloro-N-[2-[2-[(2,5-dichlorophenyl)sulfonylamino]ethyldisulfanyl]ethyl]benzenesulfonamide;94C2DMM81L;N,N'-(Dithiodi-2,1-ethanediyl)bis[2,5-dichloro-benzenesulfonamide;AOB3033;BCP16036;N,N'-(Dithiodi-2,1-ethanediyl)bis(2,5-dichlorobenzenesulfonamide);s7946;KC7F2, >=98% (HPLC);AK499435;Q27271666;N,N'-(Dithiodi-2,1-ethanediyl)bis[2,5-dichlorobenzenesulfonamide;O-(2-Am
SMILES:	ClC1C([H])=C([H])C(=C([H])C=1S(N([H])C([H])([H])C([H])([H])SSC([H])([H])C([H])([H])N([H])S(C1C([H])=C(C([H])=C([H])C=1Cl)Cl)(=O)=O)(=O)=O)Cl
Formula:	C₁₆H₁₆Cl₄N₂O₄S₄
M.Wt:	570.3812
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.Target：HIFin vitro: KC7F2 is the second HIF-1α inhibitor. KC7F2 is shown to inhibit the proliferation of cancer cells, an effect that is increased in hypoxia, while non-tumor cells are less sensitive. KC7F2 decreases HIF-1α levels by downregulating HIF-1α protein synthesis. [2] KC7F2 markedly inhibits HIF-mediated transcription in cells derived from different tumor types, including glioma, breast and prostate cancers and exhibited enhanced cytotoxicity under hypoxia. KC7F2 prevents the activation of HIF-target genes such as Carbonic Anhydrase IX, Matrix Metalloproteinase 2 (MMP2), Endothelin 1 and Enolase 1. KC7F2 works through the down-regulation of HIF-1α protein synthesis, an effect accompanied by the suppression of the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and p70 S6 kinase (S6K), key regulators of HIF-1α protein synthesis.[1]

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC10339	Vadadustat	Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.
DC7486	PX-478 2HCL	PX-478 is an inhibitor of HIF-1a with an IC50 of 20-30μM enhances radiosensitivity of prostate carcinoma cells.
DC10464	PT2385	PT2385 is an orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity.
DC8390	Oltipraz	Oltipraz is a potent Nrf2 activator and a potent inducer of Phase II detoxification enzymes, most notably glutathione-S-transferase (GST). Phase 3.
DC12043	KHS-101	KHS101 is a selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 μM).
DC8447	KC7F2	KC7F2 is a potent HIF-1 pathway inhibitor and that its potential as a cancer therapy agent warrants further study.
DC8617	JNJ-42041935	JNJ-42041935 is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.
DC10825	IOX4	IOX4 is a potent inhibitor of PHD2 (IC50 = 1.6 nM).
DC8166	Molidustat(BAY 85-3934)	Hypoxia-inducible factor prolyl hydroxylase inhibitor
DC5193	Roxadustat(FG-4592)	FG-4592 is an HIF αprolyl hydroxylase inhibitor, stabilizes HIF-2 and induces EPO production.